Loading…
60 Degrees Pharmaceuticals, Inc. is projected to rise to $1.17 by 2027, a +1% move from its current price of $1.16. SXTP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.11 | $1.16 | $1.21 | -0.03% |
| Aug 6 | $1.09 | $1.16 | $1.24 | -0.06% |
| Aug 7 | $1.07 | $1.16 | $1.26 | -0.08% |
| Aug 8 | $1.06 | $1.16 | $1.27 | -0.11% |
| Aug 9 | $1.04 | $1.16 | $1.28 | -0.14% |
| Aug 10 | $1.03 | $1.16 | $1.30 | -0.17% |
| Aug 11 | $1.02 | $1.16 | $1.31 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.02 | $1.16 | $1.31 | -0.19% |
| Week 2 | $0.9718 | $1.16 | $1.37 | -0.39% |
| Week 3 | $0.9329 | $1.15 | $1.43 | -0.58% |
| Week 4 | $0.901 | $1.15 | $1.47 | -0.77% |
| Week 5 | $0.8736 | $1.15 | $1.51 | -0.96% |
| Week 6 | $0.8495 | $1.15 | $1.55 | -1.15% |
| Week 7 | $0.8277 | $1.14 | $1.58 | -1.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.
The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc.
was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP is the stock symbol for 60 Degrees Pharmaceuticals, Inc. and is currently priced at $1.25 per share. The company has a market cap of $3.32M and is ranked 5090 by market capitalization.
The forecast landscape for SXTP spans 2026 through 2050, showing a path that starts near the current level and evolves over time. In 2026 the average forecast is $1.25, with a 2027 average also $1.25, and a dip to around $0.99 for 2029 before rising again toward the 2040s. The long-horizon outlook reaches average prices of about $2.04 by 2040 and $2.56 by 2050, suggesting meaningful upside later in the horizon.
Across the forecast, max projected prices climb to $4.20 in 2040 and to $5.89 in 2050, with corresponding ROI figures of 63.6% and 104.8% and sentiment shifting toward bullish in the distant years. These numbers depict a probabilistic, not guaranteed, path for the asset with notable variability year by year.
A major floor 34.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.9% away) — a key level to hold.
The nearest ceiling, 53.4% above — a clean break opens room to run.
A major ceiling 91.4% above — clearing it would confirm fresh momentum.
Key SXTP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SXTP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.40 | Sell | $1.34 | Sell |
| MA 10 | $1.46 | Sell | $1.42 | Sell |
| MA 20 | $1.50 | Sell | $1.48 | Sell |
| MA 50 | $1.52 | Sell | $1.56 | Sell |
| MA 100 | $1.65 | Sell | $1.90 | Sell |
| MA 200 | $2.74 | Sell | $4.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.47 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -304.87 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -24.52 | Sell |
| Bollinger %B (20,2) | -0.25 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.22 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 22.83 | Buy |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.29 | Sell |
| ADX (14) | 15.23 | Neutral |
| ATR (14) | 0.06 | Info |
The near-term technical picture is bearish. The RSI(14) sits at 30, indicating renewed downside momentum, while the 50-day simple moving average sits at $1.53 and the 200-day simple moving average sits at $2.77.
Near-term support is identified at $1.25, with resistance at $1.78. The 30-day price range runs from a low of $0.9215 to a high of $1.70, highlighting a constrained trading band in the most recent month. Volatility is elevated, reflecting risk given the stock’s current trajectory.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.16 | $1.16 | $1.44 | 0% | Neutral | |
| $0.8714 | $1.17 | $1.68 | +1% | Neutral | |
| $0.7574 | $1.07 | $1.63 | -8% | Neutral | |
| $0.6216 | $0.9149 | $1.46 | -21% | Bearish | |
| $0.6574 | $1.01 | $1.67 | -13% | Neutral | |
| $0.6885 | $1.09 | $1.87 | -6% | Neutral | |
| $0.8415 | $1.38 | $2.43 | +19% | Neutral | |
| $0.894 | $1.52 | $2.74 | +31% | Bullish | |
| $0.7178 | $1.26 | $2.32 | +8% | Neutral | |
| $0.7408 | $1.34 | $2.52 | +15% | Neutral | |
| $0.9118 | $1.91 | $3.92 | +64% | Bullish | |
| $1.06 | $2.35 | $5.40 | +102% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.16 | $1.16 | $1.40 | +0.00% |
| September 2026 | $0.9681 | $1.17 | $1.46 | +0.67% |
| October 2026 | $0.9266 | $1.13 | $1.44 | -3.14% |
| November 2026 | $0.8659 | $1.07 | $1.38 | -5.63% |
| December 2026 | $0.881 | $1.10 | $1.44 | +2.67% |
Click any year to see its month-by-month SXTP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SXTP price prediction for 2026 points to an average of $1.16 (low $1.16, high $1.44) — a potential gain of 0% on today's $1.16. Price action looks broadly range-bound.
In 2027, SXTP is projected to trade between $0.8714 and $1.68, averaging $1.17 — a potential gain of +1% from today's $1.16. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
60 Degrees Pharmaceuticals, Inc.'s 2028 outlook centres on $1.07, within a $0.7574 to $1.63 range. That is -8% versus the projected 2027 average. That marks a -8% change versus current levels. Price action looks broadly range-bound.
By 2029, SXTP could reach as high as $1.46, with a base case around $0.9149 and support toward $0.6216 — roughly -21% from $1.16. Expect choppier, lower action through this leg of the cycle.
Expect SXTP to range from $0.6574 to $1.67 through 2030. The $1.01 average target implies a -13% move from current prices. That is up +10% on the projected 2029 average. Price action looks broadly range-bound.
The SXTP price prediction for 2031 points to an average of $1.09 (low $0.6885, high $1.87) — a potential decline of -6% on today's $1.16. A consolidation phase looks the most probable path here.
In 2032, SXTP is projected to trade between $0.8415 and $2.43, averaging $1.38 — a potential gain of +19% from today's $1.16. That is up +26% on the projected 2031 average. Price action looks broadly range-bound.
60 Degrees Pharmaceuticals, Inc.'s 2033 outlook centres on $1.52, within a $0.894 to $2.74 range. That is up +10% on the projected 2032 average. That marks a +31% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SXTP could reach as high as $2.32, with a base case around $1.26 and support toward $0.7178 — roughly +8% from $1.16. Price action looks broadly range-bound.
Expect SXTP to range from $0.7408 to $2.52 through 2035. The $1.34 average target implies a +15% move from current prices. That is up +6% on the projected 2034 average. A consolidation phase looks the most probable path here.
The SXTP price prediction for 2040 points to an average of $1.91 (low $0.9118, high $3.92) — a potential gain of +64% on today's $1.16. Momentum favours further upside here.
In 2050, SXTP is projected to trade between $1.06 and $5.40, averaging $2.35 — a potential gain of +102% from today's $1.16. That is up +23% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SXTP today (≈ 862.068966 SXTP) could be worth
$2,024.77
+$1,024.77 (+102%) by 2050 · US Dollar
Based on the average projected SXTP price of $2.35 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SXTPwould be worth at today's price.
$1,000 invested in SXTP on Jul 31, 2025 (≈ 186.56716 SXTP) would be worth
$216.42
-$783.58 (-78.4%) today · 0.22× · US Dollar
Based on a SXTP entry price of $5.36 vs. today's $1.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.48 | $783.78 | -21.6% |
| 1 month ago | $1.75 | $662.86 | -33.7% |
| 3 months ago | $1.66 | $698.8 | -30.1% |
| 6 months ago | $3.64 | $318.68 | -68.1% |
| 1 year ago | $5.36 | $216.42 | -78.4% |
| All time (3.1y) ago | $1,123.2 | $1.03 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SXTP forecast.
Our base-case forecast reaches $2.30 around 2050.
Implied market cap at $2.30: $6.12M
The multi-year forecast shows a mixed path with periods of neutral sentiment followed by overt bullishness in later years. For 2026 the min is $1.25, avg $1.25, max $1.56, ROI 0, sentiment NEUTRAL; for 2027 the min is $0.9352, avg $1.25, max $1.80, ROI 0.1, sentiment NEUTRAL. The year 2028 carries a min of $0.8135, avg $1.15, max $1.75, ROI -8.3, sentiment NEUTRAL, and 2029 shows a further dip to min $0.6732, avg $0.9912, max $1.58, ROI -20.7, sentiment BEARISH.
2030 presents min $0.7051, avg $1.08, max $1.79, ROI -13.6, sentiment NEUTRAL, while 2031 offers min $0.7447, avg $1.18, max $2.02, ROI -5.4, sentiment NEUTRAL.
The forecast turns more positive in 2032 (min $0.9117, avg $1.50, max $2.63, ROI 19.8, sentiment NEUTRAL) and 2033 (min $0.9574, avg $1.63, max $2.93, ROI 30, sentiment BULLISH). By 2040 the average price is forecast at $2.04 with a max of $4.20, ROI 63.6, and sentiment BULLISH. The 2050 outlook shows an average of $2.56, a max of $5.89, a min of $1.15, ROI 104.8, and sentiment BULLISH.
These are estimates, not guarantees, and reflect a wide range of possible outcomes.
Tap a question to reveal the answer.
For 2030, the forecast lists min $0.7051, avg $1.08, max $1.79, ROI -13.6%, sentiment NEUTRAL.
The forecast shows neutral sentiment in 2026-2027 with later years turning bullish (2033, 2040, and 2050). Notable upside is possible in 2040 (avg $2.04, max $4.20, ROI 63.6%) and 2050 (avg $2.56, max $5.89, ROI 104.8%), but earlier years include negative or flat returns and periods of neutrality.
Yes. The 2050 forecast lists a max of $5.89, with an average of $2.56 and min of $1.15, and a bullish sentiment. The ROI for 2050 is 104.8%.
The 2040 forecast has an average price of $2.04, with a min of $0.9781 and a max of $4.20, ROI 63.6%, and sentiment BULLISH.
The current price is $1.25 per share. The market cap is $3.32M, and the rank is 5090.
60 Degrees Pharmaceuticals, Inc. Community Discussion
0Share your 60 Degrees Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.